BravoBio is an advanced biotechnology company that specializes in the  development of innovative human  vaccines. It is committed to developing novel vaccines to combat a range of infectious diseases, including Human  papillomavirus (HPV), varicella-zoster virus (VZV), respiratory syncytial virus (RSV), rotavirus, and bacterial infections.

       The company enhances vaccine research,development, and large-scale production in line with global benchmarks. Its success stems from its  profound understanding of fundamental basic sciences, which include pathology, immunology, molecular sciences, structural biology, and biochemistry. BravoBio delivers quality vaccines by continuously improving its market knowledge, expertise,  production capabilities, and high-tech facilities.

       “Our unique synergy of cutting-edge technologies,  strategic collaborations, and rigorous analyses enables us to create novel human vaccines that not only address emerging  infectious diseases but also redefine the standards of safety, efficacy, and accessibility,” says Dr. Ke Wu, founder and CEO of BravoBio.

Dr. Ke Wu,Founder,and CEO

        The company’s commitment to technical innovations  remains steadfast as it harnesses a wide range of advanced technologies, including recombinant technology, cell culture, fermentation, and viral-vectored technology, to develop optimalvaccines. These serve as the backbone of its research,  enabling the company to concurrently explore multiple  paths and methods for vaccine development. The parallel experiments, conducted using various approaches, assist developers in identifying the safest and most cost-effective vaccine candidate.

         Striving to develop quality vaccines, the company  uses a variety of analytical methodologies to acquire  an in-depth understanding of its product, spanning from  molecular dimensions to comprehensive chemical, physical, and biological attributes. These insights are aligned with Pharmacopoeia standards, which ensure the quality and safety of essential medicines through defined analytical methods and appropriate limits for evaluating active ingredients, excipients, and finished products. In developing new products without any prior indices in the pharmacopoeia, the company creates new  standard operating procedures (SOPs) and methodologies with the help of its multifaceted technology and a network of highly qualified researchers.

         BravoBio understands the value of partnerships in accelerating vaccine  development. The company joins forces with  its industry-specific leaders to identify and stay  informed about the new developments, trends,  and innovations in the vaccine industry. When a  promising technology emerges, it contacts the  original developers and establishes collaborative  links to provide access to licensing and sub- licensing opportunities. This synergy and the  company’s high-tech facilities help developers  transit from concept to tangible product development.

          The company also engages with pioneers and experts in  the field to gain access to their groundbreaking technologies.  By utilizing its robust research capabilities in human vaccine  development, the company employs an innovative strategy to  compare its candidates with established commercial products. BravoBio strengthens these candidates by working with  esteemed institutions and researchers. This head-to-head  evaluation, conducted in vitro and in vivo, enables the company to fine-tune its vaccines for optimal safety and efficacy.

        One of the company’s many notable achievements is the  approval of its universal human papillomavirus (HPV) vaccine  for clinical trials by the Therapeutic Goods Administration  (TGA) in Australia. It is the first universal HPV vaccine that  enters the clinical stage and can protect against more than 200 serotypes of HPV theoretically.

         Another remarkable achievement by BravoBio is the development of an inhaled vaccine delivery method for COVID-19. The company recognized the potential of inhaled  administration and devised a non-invasive, nebulization-based vaccine. This unique strategy garnered recognition from the  World Health Organization (WHO) even before the vaccine  received full regulatory approval. The vaccine is making  significant progress globally, with clinical authorization across continents demonstrating BravoBio's innovation.

        The company and its subsidiary, BravoVax, embody a unique combination of scientific prowess, technological finesse, and strategic collaboration dedicated to advancing human health. The company continues to pioneer new  vaccine technologies, develop new methodologies, and forge meaningful relationships while remaining at the forefront of  revolutionizing human vaccine development. Through its groundbreaking work, BravoBio aims to safeguard humans against a broad spectrum of infectious diseases for a healthier and happier future.